Piper Jaffray Companies reaffirmed their buy rating on shares of Rewalk Robotics (NASDAQ:RWLK) in a research note issued to investors on Sunday morning. Piper Jaffray Companies currently has a $3.00 price target on the medical device company’s stock.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity restated a buy rating and issued a $3.00 target price on shares of Rewalk Robotics in a research note on Monday, November 6th. Oppenheimer set a $3.00 price objective on shares of Rewalk Robotics and gave the company a buy rating in a research note on Tuesday, December 26th. Zacks Investment Research cut shares of Rewalk Robotics from a buy rating to a hold rating in a research note on Thursday. Finally, Jefferies Group reduced their price objective on shares of Rewalk Robotics from $8.00 to $5.00 and set a buy rating for the company in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Rewalk Robotics presently has a consensus rating of Buy and a consensus price target of $2.83.

Rewalk Robotics (NASDAQ RWLK) traded down $0.02 during mid-day trading on Friday, hitting $1.10. 207,542 shares of the stock traded hands, compared to its average volume of 459,682. Rewalk Robotics has a one year low of $1.05 and a one year high of $3.60. The firm has a market cap of $31.82, a PE ratio of -0.69 and a beta of 0.79. The company has a debt-to-equity ratio of 7.46, a current ratio of 2.02 and a quick ratio of 1.65.

Rewalk Robotics (NASDAQ:RWLK) last released its earnings results on Thursday, November 2nd. The medical device company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.10. Rewalk Robotics had a negative net margin of 346.14% and a negative return on equity of 568.25%. The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $1.63 million. During the same quarter last year, the business earned ($0.62) EPS. The business’s revenue was up 21.4% on a year-over-year basis. equities research analysts forecast that Rewalk Robotics will post -1.14 earnings per share for the current year.

A hedge fund recently raised its stake in Rewalk Robotics stock. Essex Investment Management Co. LLC lifted its stake in Rewalk Robotics Ltd (NASDAQ:RWLK) by 328.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 156,981 shares of the medical device company’s stock after purchasing an additional 120,362 shares during the period. Essex Investment Management Co. LLC owned approximately 0.72% of Rewalk Robotics worth $228,000 as of its most recent SEC filing. Institutional investors and hedge funds own 3.23% of the company’s stock.

WARNING: “Rewalk Robotics’ (RWLK) “Buy” Rating Reiterated at Piper Jaffray Companies” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2018/01/08/rewalk-robotics-rwlk-buy-rating-reiterated-at-piper-jaffray-companies.html.

About Rewalk Robotics

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.

Analyst Recommendations for Rewalk Robotics (NASDAQ:RWLK)

Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.